Scientists at the Wellcome Sanger Institute, EMBL’s European Bioinformatics Institute and AstraZeneca combined drug response data with CRISPR genetic screens across hundreds of cancer cell lines to better understand how drugs target cancer cells.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
